Drug interactions and pharmacokinetics: latest news

Drug interactions and pharmacokinetics resources

Drug interactions and pharmacokinetics features

Drug interactions and pharmacokinetics news from aidsmap

More news

Drug interactions and pharmacokinetics news selected from other sources

  • Top five concerns people with HIV have about ageing: Scotland

    Through the Positive Persons' Forum and other initiatives, many people with HIV in Scotland have made it clear that they are very concerned about growing older with HIV. We have set out some of these concerns in the infographic below (or view it as a plain online image). The top 5 concerns were confidentiality, the effects of HIV medication, drug interactions, Financial stability and ignorance and stigma.

    12 August 2015 | HIV Scotland-
  • 'Lab on a card' can spot poor quality drugs

    The tool is known as a PAD (Paper Analytical Device) and is essentially a mini lab on a piece of card, Mercy explains. "It's simple, you apply the tablet on a specific area on the device, dip the card in water and wait for a colour reaction, then compare the results to a standard to interpret the results." Each of the cards contains 12 separate strips which react with a drug to create a "coloured bar code" that gives information about its chemical content.

    08 June 2015 | BBC Health
  • Almost Three Quarters of HIV/HCV Group May Have DDA-ARV Interactions

    Among 125 HIV/HCV-coinfected people taking antiretrovirals in a Denver group, 70% could have moderate or severe interactions with one of four common direct-acting antiviral (DAA) regimens for HCV.

    02 June 2015 | NATAP
  • Isentress (raltegravir) label update

    On February 18, 2015, FDA approved changes to the Isentress (raltegravir) label to include updated information regarding the coadministration of raltegravir and aluminum and/or magnesium containing antacid.

    19 February 2015 | FDA
  • Viral Load Reductions Persist With Less Efavirenz for HIV

    The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

    07 November 2014 | Medscape (requires free registration)
  • Change to recommended regimen for post-exposure prophylaxis (PEP)

    The Expert Advisory Group on AIDS (EAGA) has recommended a change in the recommended regimen for post-exposure prophylaxis from tenofovir/emtricitabine with Kaletra to tenofovir/emtricitabine with raltegravir.

    11 September 2014 | Expert Advisory Group on AIDS (EAGA)
  • Dosage of HIV drug may be ineffective for half of African-Americans

    Many African-Americans may not be getting effective doses of the HIV drug maraviroc. The initial dosing studies included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body, resulting in higher concentrations of the drug in the blood. The current study shows that people with maximum levels of the protein CYP3A5 -- including nearly half of African-Americans -- end up with lower levels of maraviroc in their bodies.

    28 August 2014 | Eurekalert Medicine & Health
  • Opioid Therapy No Bar to Novel HCV Drugs

    People on opioid substitution therapy for drug addiction can be safely and effectively treated for hepatitis C (HCV) with an investigational combination of medications, researchers said here.

    24 July 2014 | MedPage Today
  • Advice on Best ART Regimen for Patients Taking Cancer Therapy

    Because no clinical trials address the question and published data are insufficient to support guidelines, the optimal antiretroviral therapy (ART) regimen for patients undergoing cancer chemotherapy remains unknown. But experts from Houston’s M.D. Anderson Cancer Center offer suggestions to help clinicians individualize therapy for each patient.

    25 June 2014 | International AIDS Society
  • In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

    Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

    02 June 2014 | Medscape
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.